Key Points:
- Leading South Korean pharmaceutical manufacturers invested over 100 billion won ($72.13 million) each into new drug research during the first half of the year.
- Hanmi Pharm led total spending at 125.5 billion won, dedicating 14.6% of revenue to developing advanced obesity and metabolic treatments.
- Yuhan Corp. and Chong Kun Dang injected 122.2 billion won and 113.5 billion won, respectively, expanding investments in global oncology and rare disease pipelines.
- Domestic drugmakers are reinvesting 10% to 15% of their total revenues into clinical pipelines to transition into innovative global biopharma players.
South Korea’s leading pharmaceutical corporations are accelerating their research and development investments to secure long-term global growth engines. Official regulatory filings reveal that major domestic drugmakers spent well over 100 billion won, equivalent to roughly $72.13 million, each on new drug development during the first six months of the year. The heavy capital deployment marks an industry-wide transition away from reliance on domestic generic formulations toward developing high-margin, proprietary blockbuster treatments for international markets.
Yuhan Corp., widely recognized for its household anti-inflammatory ointment Antiphlamine, reported a total research investment of 122.2 billion won during the January-to-June period. This outlay represents a 13.8% increase compared to the same timeframe of the previous year, accounting for 10.5% of the company’s total first-half sales. The enterprise is channeling substantial capital into expanding its global oncology pipeline, building on the international clinical success of its non-small cell lung cancer therapy Leclaza.
Chong Kun Dang Pharmaceutical Corp., famous for its staple household pain reliever Penzal, posted one of the most aggressive research increases in the sector. The company injected 113.5 billion won into new drug research during the first half of the year, representing 12.3% of its total revenue. This capital allocation reflects a sharp 36.6% jump compared to its research spending in the first half of 2025. The enterprise is using these funds to advance novel small-molecule treatments, antibody-drug conjugates, and rare disease candidates following major international licensing partnerships.
Hanmi Pharm Co. emerged as the biggest spender in terms of both total capital and revenue percentage. The company poured 125.5 billion won into research and development during the first half of the year, dedicating an industry-leading 14.6% of its half-year sales to clinical discovery. The massive capital deployment supports the company’s dedicated obesity pipeline initiative launched in 2023. Known as the Hanmi Obesity Pipeline, the project focuses on developing next-generation GLP-1 receptor agonists and multi-target therapies designed to deliver superior weight loss with fewer muscle-loss side effects.
Other major domestic pharmaceutical leaders demonstrated a matching commitment to research innovation. Daewoong Pharma invested 115.7 billion won into research and clinical trials during the first half of the year, channeling funds into global expansion programs for its gastroesophageal reflux drug Fexuclue and novel diabetes treatments. Meanwhile, vaccine and plasma specialist GC Biopharm directed 85.9 billion won toward research, focusing heavily on rare disease therapeutics and immunology treatments following the United States market entry of its primary blood-derived products.
The trend of aggressive research spending extends across mid-sized Korean pharmaceutical companies as well. Mid-tier drugmakers consistently allocated roughly 10% or more of their first-half sales toward new drug discovery. Rather than competing in crowded domestic price wars over generic drugs, mid-sized enterprises are carving out specialized niches in autoimmune diseases, ocular therapies, and novel bio-better formulations to license assets to multinational pharmaceutical giants.
This sustained research acceleration reflects a fundamental transformation in South Korea’s pharmaceutical business model. Historically, domestic drugmakers generated steady cash flows by distributing licensed foreign medications and manufacturing generic copycat drugs for local hospitals. However, as domestic pricing regulations and government health insurance reimbursements tighten, Korean drugmakers are prioritizing proprietary novel drug discoveries capable of securing marketing approvals from the United States Food and Drug Administration and the European Medicines Agency.
The corporate spending surge aligns with national strategic roadmaps to develop biotechnology into a core industrial pillar alongside semiconductors and electric vehicle batteries. Government agencies are supporting corporate research through tax credits, streamlined clinical trial approvals, and dedicated public-private biopharma investment funds. These supportive policies encourage domestic companies to maintain double-digit research reinvestment rates even during broader macroeconomic uncertainties.
By collectively investing hundreds of billions of won into early-stage discovery and late-stage clinical trials, South Korea’s pharmaceutical heavyweights are establishing a formidable pipeline of next-generation therapies. As global demand for innovative treatments in oncology, obesity, and immunology accelerates, these sustained research outlays ensure that Korean drugmakers are well-positioned to commercialize blockbuster treatments and claim a larger share of the international healthcare market.
